SGLT2 Inhibitors and Safety in Older Patients

Zinman B. Wanner C. et al.

Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.

N Engl J Med. 2015; 373: 2117-2128Wanner C. Inzucchi S.E. Lachin J.M. et al.

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

N Engl J Med. 2016; 375: 323-334Neal B. Perkovic V. Mahaffey K.W. et al.

Canagliflozin and cardiovascular and renal events in type 2 diabetes.

N Engl J Med. 2017; 377: 644-657Wiviott S.D. Raz I. Bonaca M.P. et al.

Dapagliflozin and cardiovascular outcomes in type 2 diabetes.

N Engl J Med. 2019; 380: 347-357McMurray J. Solomon S. Inzucchi S. et al.

Dapagliflozin in patients with heart failure and reduced ejection fraction.

N Engl J Med. 2019; 381: 1995-2008Packer M. Anker S.D. Butler J. et al.

Cardiovascular and renal outcomes with empagliflozin in heart failure.

N Engl J Med. 2020; 383: 1413-1424Anker S.D. Butler J. Filippatos G. et al.

Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-REDUCED trial.

Circulation. 2021; 143: 337-349Groenewegen A. Rutten F.H. Mosterd A. et al.

Epidemiology of heart failure.

Eur J Heart Fail. 2020; 22: 1342-1356

International Diabetes Federation. IDF Diabetes Atlas, 10th edn Brussels, Belgium.

(Available at:) (Accessed April 1, 2022)Zazzara M.B. Palmer K. Liborio Vetrano D. et al.

Adverse drug reactions in older adults: a narrative review of the literature.

Eur Geriatr Med. 1999; 12: 463-473Lombardi F. Paoletti L. Carrieri B. et al.

Underprescription of medications in older adults: causes, consequences and solutions-a narrative review.

Eur Geriatr Med. 2021; 12: 453-462Abdul-Ghani M.A. DeFronzo R.A. Norton L.

Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans.

Diabetes. 2013; 62: 3324-3328Zhang L. Feng Y. List J. et al.

Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight.

Diabetes Obes Metab. 2010; 12: 510-516

Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease.

Clin Pharmacokinet. 2015; 54: 691-708

FDA. U.S. Food and Drug Administration; Drug Safety Communications.

(Available at:) (Accessed April 1, 2022)Martinez F.A. Serenelli M. Nicolau J.C. et al.

Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF.

Circulation. 2020; 141: 100-111Cahn A. Mosenzon O. Wiviott S.D. et al.

Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE-TIMI 58 study.

Diabetes Care. 2020; 43: 468-475Monteiro P. Bergenstal R.M. Toural E. et al.

Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial.

Age Ageing. 2019; 48: 859-866Mordi N.A. Mordi I.R. Singh J.S. et al.

Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the RECEDE-CHF trial.

Circulation. 2020; 142: 1713-1724Jackson A.M. Dewan P. Anand I.S. et al.

Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF.

Circulation. 2020; : 1040-1054Qiu M. Ding L.L. Zhang M. et al.

Safety of four SGLT2 inhibitors in three chronic diseases: a meta-analysis of large randomized trials of SGLT2 inhibitors.

Diabetes Vasc Dis Res. 2021; 18: 1-3Kinduryte Schorling O. Clark D. Zwiener I. et al.

Pooled safety and tolerability analysis of empagliflozin in patients with type 2 diabetes mellitus.

Adv Ther. 2020; 37: 3463-3484Sinclair A.J. Bode B. Harris S. et al.

Efficacy and safety of canagliflozin in individuals aged 75 and older with type 2 diabetes mellitus: a pooled analysis.

Wiley Online Libr. 2016; 64: 543-552Pratley R. Dagogo-Jack S. Charbonnel B. et al.

Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: a pooled analysis of phase III studies.

Wiley Online Libr. 2020; 22: 2276-2286Cahn A. Melzer-Cohen C. Diabetes R.P.

Obesity undefined, 2019‏ undefined. Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: real-world data analysis.

Wiley Online Libr. 2018; 21: 340-348Menne J. Dumann E. Haller H. et al.

Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis.

PLOS Med. 2019; 16: e1002983Iskander C. Cherney D.Z. Clemens K.K. et al.

Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study.

CMAJ. 2020; 192: E351-E360

Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.

Nat Rev Endocrinol. 2020; 16: 556-577Cahn A. Raz I. Bonaca M. et al.

Safety of dapagliflozin in a broad population of patients with type 2 diabetes: analyses from the DECLARE-TIMI 58 study.

Diabetes Obes Metab. 2020; 22: 1357-1368Liu J. Li L. Li S. et al.

Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.

Diabetes Obes Metab. 2020; 22: 1619-1627Heerspink H.J.L. Stefánsson B.V. Correa-Rotter R. et al.

Dapagliflozin in patients with chronic kidney disease.

N Engl J Med. 2020; 383: 1436-1446Ueda P. Svanström H. Melbye M. et al.

Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: Nationwide register based cohort study.

BMJ. 2018; 363: 4365Rosenstock J. Ferrannini E.

Euglycemic diabetic ketoacidosis: A predictable, detectable, and preventable safety concern with sglt2 inhibitors.

Diabetes Care. 2015; 38: 1638-1642

16. Diabetes care in the hospital: standards of medical care in diabetes—2022.

Diabetes Care. 2022; 45: S244-S253Kuhre R.E. Deacon C.F. Wewer Albrechtsen N.J. et al.

Do sodium-glucose co-transporter-2 inhibitors increase plasma glucagon by direct actions on the alpha cell? And does the increase matter for the associated increase in endogenous glucose production?.

Diabetes Obes Metab. 2021; 23: 2009-2019

Careful use to minimize adverse events of oral antidiabetic medications in the elderly.

Expert Opin Pharmacother. 2021; 22: 2149-2165

13. older adults: standards of medical care in diabetes—2022.

Diabetes Care. 2022; 45: S195-S207Farooqui K.J. Mithal A. Kerwen A.K. et al.

Type 2 diabetes and bone fragility- An under-recognized association.

Diabetes Metab Syndr Clin Res Rev. 2021; 15: 927-935Schwartz A.V. Vittinghoff E. Bauer D.C. et al.

Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes.

JAMA. 2011; 305: 2184-2192Perkovic V. Jardine M.J. Neal B. et al.

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.

N Engl J Med. 2019; 380: 2295-2306Jabbour S. Seufert J. Scheen A. et al.

Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb/III clinical trials.

Diabetes Obes Metab. 2018; 20: 620-628Qian B.B. Chen Q. Li L. et al.

Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials.

Osteoporos Int. 2020; 31: 2313-2320Han S.J. Ha K.H. Lee N. et al.

Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a nationwide population-based study.

Diabetes Obes Metab. 2021; 23: 682-691Zhuo M. Hawley C.E. Paik J.M. et al.

Association of sodium-glucose cotransporter–2 inhibitors with fracture risk in older adults with type 2 diabetes.

JAMA Netw Open. 2021; 4: e2130762Geerlings S. Fonseca V. Castro-Diaz D. et al.

Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria.

Diabetes Res Clin Pract. 2014; 103: 373-381Puckrin R. Saltiel M.P. Reynier P. et al.

SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials.

Acta Diabetol. 2018; 55: 503-514Dave C.V. Schneeweiss S. Kim D. et al.

Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections.

Ann Intern Med. 2019; 171: 248-256

An update on the safety of SGLT2 inhibitors.

Expert Opin Drug Saf. 2019; 18: 295-311Lega I.C. Bronskill S.E. Campitelli Msc M.A. et al.

Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: a population-based study of older women and men with diabetes.

Wiley Online Libr. 2019; 21: 2394-2404McGovern A.P. Hogg M. Shields B.M. et al.

Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation.

BMJ Open Diabetes Res Care. 2020; 8: e001238Fralick M. Kim S.C. Schneeweiss S. et al.

Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study.

BMJ. 2020; 370: 2812Chang H.Y. Singh S. Mansour O. et al.

Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes.

JAMA Intern Med. 2018; 178: 1242-1248Yu O.H.Y. Dell’Aniello S. Shah B.R. et al.

Sodium–glucose cotransporter 2 inhibitors and the risk of below-knee amputation: a multicenter observational study.

Diabetes Care. 2020; 43: 2444-2452Alshnbari A. Alkharaiji M. Anyanwagu U. et al.

Diuretics and risk of lower extremity amputation amongst patients with insulin-treated type 2 diabetes–exploring the mechanism of possible sodium glucose co-transporter 2 inhibitor induced risk of lower extremity amputations.

Curr Med Res Opin. 2020; 36: 1985-1989

Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: a trial-level meta-analysis including 51 713 individuals.

Diabetes Obes Metab. 2020; 22: 2348-2355

留言 (0)

沒有登入
gif